Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Multi-Country, Multicenter, Single-Arm, Open-Label Study to Document the Safety, Tolerability and Effect of Alirocumab on Atherogenic Lipoproteins in High Cardio-Vascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-Modifying Therapies

    Summary
    EudraCT number
    2015-000620-28
    Trial protocol
    DK   CZ   SK   BE   IT   HU   AT   DE   FR   SE   ES   FI   PL   GR   SI  
    Global end of trial date
    12 Apr 2019

    Results information
    Results version number
    v1(current)
    This version publication date
    25 Apr 2020
    First version publication date
    25 Apr 2020
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    LPS14245
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT02476006
    WHO universal trial number (UTN)
    U1111-1163-0984
    Other trial identifiers
    Study Name: ODYSSEY APPRISE
    Sponsors
    Sponsor organisation name
    Sanofi-Aventis Recherche & Développement
    Sponsor organisation address
    1 avenue Pierre Brossolette, Chilly-Mazarin, France, 91380
    Public contact
    Trial Transparency Team, Sanofi aventis recherche & développement, Contact-US@sanofi.com
    Scientific contact
    Trial Transparency Team, Sanofi aventis recherche & développement, Contact-US@sanofi.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    28 May 2019
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    12 Apr 2019
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To provide access to alirocumab ahead of commercial availability and to document the overall safety and tolerability of alirocumab in subjects with severe hypercholesterolemia at risk for subsequent cardiovascular (CV) events and not adequately controlled with currently available lipid-modifying therapy (LMT).
    Protection of trial subjects
    Subjects were fully informed of all pertinent aspects of the clinical trial as well as the possibility to discontinue at any time in language and terms appropriate for the subject and considering the local culture. During the course of the trial, subjects were provided with individual subject cards indicating the nature of the trial the subject is participating, contact details and any information needed in the event of a medical emergency. Collected personal data and human biological samples were processed in compliance with the Sanofi-Aventis Group Personal Data Protection Charter ensuring that the Group abides by the laws governing personal data protection in force in all countries in which it operates.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    23 Jun 2015
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Canada: 131
    Country: Number of subjects enrolled
    Switzerland: 30
    Country: Number of subjects enrolled
    Poland: 40
    Country: Number of subjects enrolled
    Romania: 7
    Country: Number of subjects enrolled
    Slovakia: 12
    Country: Number of subjects enrolled
    Slovenia: 3
    Country: Number of subjects enrolled
    Spain: 92
    Country: Number of subjects enrolled
    Austria: 40
    Country: Number of subjects enrolled
    Belgium: 68
    Country: Number of subjects enrolled
    Czech Republic: 35
    Country: Number of subjects enrolled
    Denmark: 23
    Country: Number of subjects enrolled
    Finland: 8
    Country: Number of subjects enrolled
    France: 215
    Country: Number of subjects enrolled
    Germany: 10
    Country: Number of subjects enrolled
    Greece: 15
    Country: Number of subjects enrolled
    Hungary: 10
    Country: Number of subjects enrolled
    Italy: 255
    Worldwide total number of subjects
    994
    EEA total number of subjects
    833
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    722
    From 65 to 84 years
    269
    85 years and over
    3

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The study was conducted at 156 sites in 17 countries. A total of 1305 subjects were screened between 23-June-2015 to 27-December 2016, of whom 307 were screen failures. Screen failures were mainly due to exclusion criteria met.

    Pre-assignment
    Screening details
    A total of 998 subjects were enrolled in the study. Out of which, 994 subjects were treated.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Arm title
    Alirocumab
    Arm description
    Subjects received Alirocumab 150 milligram (mg) subcutaneously (SC) once every two weeks (Q2W) or 75 mg SC Q2W added to stable LMT up to a maximum of 120 weeks. Alirocumab dose was either up-titrated from 75 to 150 mg Q2W or down-titrated from 150 to 75 mg Q2W, based on Investigator judgment and treatment response.
    Arm type
    Experimental

    Investigational medicinal product name
    Alirocumab
    Investigational medicinal product code
    SAR236553, REGN727
    Other name
    Praluent®
    Pharmaceutical forms
    Solution for injection in pre-filled pen
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Subject received Alirocumab 150 mg or 75 mg SC Q2W as per Investigator judgement in the abdomen, thigh, or outer area of upper arm.

    Number of subjects in period 1
    Alirocumab
    Started
    994
    Treated
    994
    Completed
    878
    Not completed
    116
         Adverse Event
    41
         Physician Decision
    5
         Poor compliance to study protocol
    3
         Sponsor decision
    6
         Excluded from study
    1
         Switched to commercial drug
    4
         Study ended treatment not available
    4
         Death
    4
         Lost to Follow-up
    5
         Pregnancy
    1
         Subject did not wish to continue
    39
         Protocol Violation
    1
         Lack of treatment efficacy
    2

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Alirocumab
    Reporting group description
    Subjects received Alirocumab 150 milligram (mg) subcutaneously (SC) once every two weeks (Q2W) or 75 mg SC Q2W added to stable LMT up to a maximum of 120 weeks. Alirocumab dose was either up-titrated from 75 to 150 mg Q2W or down-titrated from 150 to 75 mg Q2W, based on Investigator judgment and treatment response.

    Reporting group values
    Alirocumab Total
    Number of subjects
    994 994
    Age categorical
    Units: Subjects
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    56.6 ( 11.7 ) -
    Gender categorical
    Units: Subjects
        Female
    369 369
        Male
    625 625
    Race
    Units: Subjects
        White/Caucasian
    969 969
        Black
    10 10
        Asian/Oriental
    6 6
        Multiracial
    1 1
        Other
    8 8

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Alirocumab
    Reporting group description
    Subjects received Alirocumab 150 milligram (mg) subcutaneously (SC) once every two weeks (Q2W) or 75 mg SC Q2W added to stable LMT up to a maximum of 120 weeks. Alirocumab dose was either up-titrated from 75 to 150 mg Q2W or down-titrated from 150 to 75 mg Q2W, based on Investigator judgment and treatment response.

    Primary: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs)

    Close Top of page
    End point title
    Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) [1]
    End point description
    Adverse Event (AE) was defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as AEs that that developed or worsened or became serious during the TEAE period (time from the first injection of study drug up to the day of the last injection of study drug + 14 days). A Serious Adverse Event (SAE) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. Analysis was performed on safety population that included all subjects who had signed the informed consent form and who had received at least one dose or partial dose of alirocumab.
    End point type
    Primary
    End point timeframe
    From first injection of investigational medicinal product (IMP) up to 2 weeks after last dose of study drug (Week 120)
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: As the endpoint is descriptive in nature, no statistical analysis is provided.
    End point values
    Alirocumab
    Number of subjects analysed
    994
    Units: percentage of subjects
    number (not applicable)
        Any TEAE
    71.6
        Any treatment emergent SAE
    16.2
        Any TEAE leading to death
    0.2
        Any TEAE leading to treatment discontinuation
    4.5
    No statistical analyses for this end point

    Secondary: Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 12

    Close Top of page
    End point title
    Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 12
    End point description
    Calculated LDL-C values were obtained using the Friedewald formula. Calculated LDL-C in mg/dL from Friedewald formula (LDL cholesterol = Total cholesterol - HDL cholesterol - [Triglyceride/5]). Baseline value was defined as the last observation before the first dose of the treatment. Analysis was performed on modified intent-to-treat population (mITT): all enrolled subjects who received at least one dose or part of a dose of alirocumab and had an evaluable efficacy endpoint during the efficacy treatment period (defined as time period from the first injection of alirocumab up to the day of last injection +21 days).
    End point type
    Secondary
    End point timeframe
    Baseline, Week 12
    End point values
    Alirocumab
    Number of subjects analysed
    921
    Units: percent change
        arithmetic mean (standard deviation)
    -54.84 ( 20.06 )
    No statistical analyses for this end point

    Secondary: Percentage of Subjects Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 12

    Close Top of page
    End point title
    Percentage of Subjects Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 12
    End point description
    LDL-Cholesterol was calculated using the Friedewald formula. Percentage of subjects who reached calculated LDL-C <100 mg/dL (2.59 millimoles per litre [mmol/L]) at week 12 were reported. Analysis was performed on mITT population.
    End point type
    Secondary
    End point timeframe
    At Week 12
    End point values
    Alirocumab
    Number of subjects analysed
    921
    Units: percentage of subjects
        number (confidence interval 95%)
    74.6 (71.7 to 77.4)
    No statistical analyses for this end point

    Secondary: Percentage of Subjects Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 12

    Close Top of page
    End point title
    Percentage of Subjects Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 12
    End point description
    LDL-Cholesterol was calculated using the Friedewald formula. Percentage of subjects who reached calculated LDL-C <70 mg/dL (1.81 mmol/L) at week 12 were reported. Analysis was performed on mITT population.
    End point type
    Secondary
    End point timeframe
    At Week 12
    End point values
    Alirocumab
    Number of subjects analysed
    921
    Units: percentage of subjects
        number (confidence interval 95%)
    50.2 (46.9 to 53.4)
    No statistical analyses for this end point

    Secondary: Percentage of Subjects Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) and/or >=50% Reduction From Baseline in LDL-C at Week 12

    Close Top of page
    End point title
    Percentage of Subjects Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) and/or >=50% Reduction From Baseline in LDL-C at Week 12
    End point description
    LDL-Cholesterol was calculated using the Friedewald formula. Percentage of subjects who reached LDL-C <70 mg/dL at Week 12 and/or >=50% reduction from baseline in LDL-C at Week 12 are reported. Analysis was performed on mITT population.
    End point type
    Secondary
    End point timeframe
    At Week 12
    End point values
    Alirocumab
    Number of subjects analysed
    921
    Units: percentage of subjects
        number (confidence interval 95%)
    69.1 (66.0 to 72.0)
    No statistical analyses for this end point

    Secondary: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12

    Close Top of page
    End point title
    Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12
    End point description
    Baseline value was defined as the last observation before the first dose of the treatment. Analysis was performed on mITT population.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 12
    End point values
    Alirocumab
    Number of subjects analysed
    921
    Units: percent change
        arithmetic mean (standard deviation)
    -45.89 ( 35.82 )
    No statistical analyses for this end point

    Secondary: Percent Change From Baseline in Total Cholesterol (Total-C) at Week 12

    Close Top of page
    End point title
    Percent Change From Baseline in Total Cholesterol (Total-C) at Week 12
    End point description
    Baseline value was defined as the last observation before the first dose of the treatment. Analysis was performed on mITT population.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 12
    End point values
    Alirocumab
    Number of subjects analysed
    921
    Units: percent change
        arithmetic mean (standard deviation)
    -38.28 ( 15.20 )
    No statistical analyses for this end point

    Secondary: Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12

    Close Top of page
    End point title
    Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12
    End point description
    Baseline value was defined as the last observation before the first dose of the treatment. Analysis was performed on mITT population.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 12
    End point values
    Alirocumab
    Number of subjects analysed
    921
    Units: percent change
        arithmetic mean (standard deviation)
    4.37 ( 17.29 )
    No statistical analyses for this end point

    Secondary: Percent Change From Baseline in Triglycerides at Week 12

    Close Top of page
    End point title
    Percent Change From Baseline in Triglycerides at Week 12
    End point description
    Baseline value was defined as the last observation before the first dose of the treatment. Analysis was performed on mITT population.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 12
    End point values
    Alirocumab
    Number of subjects analysed
    921
    Units: percent change
        arithmetic mean (standard deviation)
    -8.28 ( 33.99 )
    No statistical analyses for this end point

    Secondary: Assessment of Subject's Acceptability of Self-Injection Using Self Injection Assessment Questionnaire (SIAQ): Feeling About Injections, Self Confidence, Satisfaction With Self-Injections

    Close Top of page
    End point title
    Assessment of Subject's Acceptability of Self-Injection Using Self Injection Assessment Questionnaire (SIAQ): Feeling About Injections, Self Confidence, Satisfaction With Self-Injections
    End point description
    Pre-SIAQ: consisted of 7 items grouped into 3 domains: feelings about injections, self-confidence & satisfaction with self-injection. Post-SIAQ: 21 items grouped into 6 domains: feelings about injections, self-image, self-confidence, injection-site reactions, ease of use & satisfaction with self-injection. Subjects rated each item on 5-point (or 6-point) semantic Likert-type scale, where lower numbers=worse experience. Item scores were transformed to obtain a score ranging from 0 (worst experience) to 10 (best experience). Transformed scores for items contributing to a domain were then averaged into a domain score. Each domain score ranges from 0 (worst experience) to 10 (best experience). Pre & Post-SIAQ population: subjects from the safety population who self-injected the training injection & completed a Pre-SIAQ before first self-injection, who self-injected IMP at least once during the study and completed a Post-SIAQ. Here,"n”=subjects with available data at specified time points.
    End point type
    Secondary
    End point timeframe
    Baseline (Pre-SIAQ), Week 4, Week 8, Week 12, Week 24, Week 48, Week 72, Week 96
    End point values
    Alirocumab
    Number of subjects analysed
    952
    Units: units on a scale
    arithmetic mean (standard deviation)
        Feelings about injections: Baseline (n=952)
    8.6 ( 1.8 )
        Feelings about injections: Week 4 (n=909)
    9.1 ( 1.4 )
        Feelings about injections: Week 8 (n=894)
    9.1 ( 1.4 )
        Feelings about injections: Week 12 (n=847)
    9.2 ( 1.4 )
        Feelings about injections: Week 24 (n=668)
    9.2 ( 1.4 )
        Feelings about injections: Week 48 (n=547)
    9.2 ( 1.4 )
        Feelings about injections: Week 72 (n=423)
    9.2 ( 1.4 )
        Feelings about injections: Week 96 (n=343)
    9.3 ( 1.3 )
        Self confidence: Baseline (n=943)
    6.9 ( 2.4 )
        Self confidence: Week 4 (n=905)
    8.0 ( 2.1 )
        Self confidence: Week 8 (n=889)
    8.1 ( 2.0 )
        Self confidence: Week 12 (n=844)
    8.1 ( 1.9 )
        Self confidence: Week 24 (n=666)
    8.0 ( 2.1 )
        Self confidence: Week 48 (n=548)
    8.1 ( 2.1 )
        Self confidence: Week 72 (n=420)
    8.3 ( 2.0 )
        Self confidence: Week 96 (n=340)
    8.4 ( 2.0 )
        Satisfaction with self injection: Baseline (n=918)
    7.2 ( 2.5 )
        Satisfaction with self-injections: Week 4 (n=906)
    8.5 ( 1.6 )
        Satisfaction with self-injections: Week 8 (n=889)
    8.7 ( 1.6 )
        Satisfaction with self-injections: Week 12 (n=842)
    8.7 ( 1.6 )
        Satisfaction with self-injections: Week 24 (n=667)
    8.6 ( 1.8 )
        Satisfaction with self-injections: Week 48 (n=542)
    8.7 ( 1.5 )
        Satisfaction with self-injections: Week 72 (n=418)
    8.8 ( 1.7 )
        Satisfaction with self-injections: Week 96 (n=338)
    8.8 ( 1.4 )
    No statistical analyses for this end point

    Secondary: Assessment of Subject's Acceptability of Self-Injection Using Self Injection Assessment Questionnaire (SIAQ): Self Image, Injection-Site Reactions, Ease of Use

    Close Top of page
    End point title
    Assessment of Subject's Acceptability of Self-Injection Using Self Injection Assessment Questionnaire (SIAQ): Self Image, Injection-Site Reactions, Ease of Use
    End point description
    Post-SIAQ: self-completed after self-injection, consisted of 21 items grouped into 6 domains: feelings about injections, self-image, self-confidence, injection-site reactions, ease of use & satisfaction with self-injection. Subjects rated each item on 5-point (or 6-point) semantic Likert-type scale, where lower numbers=worse experience. Item scores were transformed to obtain a score ranging from 0 (worst experience) to 10 (best experience) for each item. Transformed scores for items contributing to a domain were then averaged into a domain score. Each domain score ranges from 0 (worst experience) to 10 (best experience). Domain scores which are not in common with Pre-SIAQ were analyzed on the Post-SIAQ population and are reported here. POST-SIAQ population: subjects from safety population who self-injected at least once during the study and completed a POST-SIAQ regardless of completion of PRE-SIAQ. Here, 'n'= subjects with available data at specified time points.
    End point type
    Secondary
    End point timeframe
    Week 4, Week 8, Week 12, Week 24, Week 48, Week 72, Week 96
    End point values
    Alirocumab
    Number of subjects analysed
    979
    Units: units on a scale
    arithmetic mean (standard deviation)
        Self Image: Week 4 (n=929)
    9.4 ( 1.4 )
        Self Image: Week 8 (n=915)
    9.4 ( 1.4 )
        Self Image: Week 12 (n=866)
    9.4 ( 1.4 )
        Self Image: Week 24 (n=682)
    9.3 ( 1.5 )
        Self Image: Week 48 (n=560)
    9.4 ( 1.4 )
        Self Image: Week 72 (n=433)
    9.3 ( 1.5 )
        Self Image: Week 96 (n=349)
    9.4 ( 1.4 )
        Injection-site reactions: Week 4 (n=925)
    9.6 ( 0.7 )
        Injection-site reactions: Week 8 (n=907)
    9.6 ( 0.8 )
        Injection-site reactions: Week 12 (n=862)
    9.6 ( 0.7 )
        Injection-site reactions: Week 24 (n=679)
    9.5 ( 0.9 )
        Injection-site reactions: Week 48 (n=549)
    9.5 ( 0.8 )
        Injection-site reactions: Week 72 (n=431)
    9.5 ( 0.8 )
        Injection-site reactions: Week 96 (n=353)
    9.5 ( 0.8 )
        Ease of use: Week 4 (n=927)
    8.7 ( 1.5 )
        Ease of use: Week 8 (n=914)
    8.7 ( 1.6 )
        Ease of use: Week 12 (n=866)
    8.8 ( 1.6 )
        Ease of use: Week 24 (n=676)
    8.8 ( 1.6 )
        Ease of use: Week 48 (n=559)
    8.9 ( 1.4 )
        Ease of use: Week 72 (n=432)
    9.0 ( 1.5 )
        Ease of use: Week 96 (n= 353)
    9.0 ( 1.4 )
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    All AEs were collected from first injection of IMP up to 2 weeks after last dose of study drug (Week 120).
    Adverse event reporting additional description
    Reported AEs were TEAEs that developed or worsened or became serious during the TEAE period (time from the first injection of study drug up to the day of the last injection of study drug + 14 days). Analysis was performed on safety population.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    21.1
    Reporting groups
    Reporting group title
    Alirocumab
    Reporting group description
    Subjects received Alirocumab 150 mg SC Q2W or 75 mg SC Q2W added to stable LMT up to a maximum of 120 weeks. Alirocumab dose was either up-titrated from 75 to 150 mg Q2W or down-titrated from 150 to 75 mg Q2W, based on Investigator judgment and treatment response.

    Serious adverse events
    Alirocumab
    Total subjects affected by serious adverse events
         subjects affected / exposed
    161 / 994 (16.20%)
         number of deaths (all causes)
    2
         number of deaths resulting from adverse events
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Benign Neoplasm Of Prostate
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Bladder Cancer Stage 0, With Cancer In Situ
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Breast Cancer
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Clear Cell Renal Cell Carcinoma
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Colon Adenoma
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal Tract Adenoma
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Lung Adenocarcinoma
         subjects affected / exposed
    2 / 994 (0.20%)
         occurrences causally related to treatment / all
    1 / 2
         deaths causally related to treatment / all
    0 / 1
    Myelodysplastic Syndrome
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Prostate Cancer
         subjects affected / exposed
    3 / 994 (0.30%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Rectal Adenocarcinoma
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Transitional Cell Carcinoma
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Uterine Cancer
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Vascular disorders
    Aortic Aneurysm
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Aortic Dissection
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Deep Vein Thrombosis
         subjects affected / exposed
    2 / 994 (0.20%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Hypertension
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Intermittent Claudication
         subjects affected / exposed
    2 / 994 (0.20%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Peripheral Arterial Occlusive Disease
         subjects affected / exposed
    2 / 994 (0.20%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Peripheral Artery Aneurysm
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Peripheral Artery Stenosis
         subjects affected / exposed
    2 / 994 (0.20%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Peripheral Artery Thrombosis
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    General disorders and administration site conditions
    Chest Discomfort
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Chest Pain
         subjects affected / exposed
    2 / 994 (0.20%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Non-Cardiac Chest Pain
         subjects affected / exposed
    2 / 994 (0.20%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Vascular Stent Stenosis
         subjects affected / exposed
    4 / 994 (0.40%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    Social circumstances
    Pregnancy Of Partner
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Reproductive system and breast disorders
    Metrorrhagia
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Prostatitis
         subjects affected / exposed
    2 / 994 (0.20%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Epistaxis
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Lung Disorder
         subjects affected / exposed
    2 / 994 (0.20%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Pulmonary Embolism
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Psychiatric disorders
    Completed Suicide
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Depression
         subjects affected / exposed
    2 / 994 (0.20%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Schizophrenia
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Product issues
    Device Dislocation
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Investigations
    Transaminases Increased
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Injury, poisoning and procedural complications
    Fall
         subjects affected / exposed
    2 / 994 (0.20%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Hip Fracture
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Injury
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Joint Injury
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Lower Limb Fracture
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Meniscus Injury
         subjects affected / exposed
    2 / 994 (0.20%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Peripheral Artery Restenosis
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Post Procedural Complication
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Post Procedural Haematoma
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Rib Fracture
         subjects affected / exposed
    2 / 994 (0.20%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Scapula Fracture
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Spinal Column Injury
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Tendon Rupture
         subjects affected / exposed
    3 / 994 (0.30%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Tibia Fracture
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Upper Limb Fracture
         subjects affected / exposed
    2 / 994 (0.20%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Vascular Graft Occlusion
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Congenital, familial and genetic disorders
    Accessory Navicular Syndrome
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cardiac disorders
    Acute Coronary Syndrome
         subjects affected / exposed
    5 / 994 (0.50%)
         occurrences causally related to treatment / all
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    Acute Myocardial Infarction
         subjects affected / exposed
    5 / 994 (0.50%)
         occurrences causally related to treatment / all
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    Angina Pectoris
         subjects affected / exposed
    15 / 994 (1.51%)
         occurrences causally related to treatment / all
    0 / 15
         deaths causally related to treatment / all
    0 / 0
    Angina Unstable
         subjects affected / exposed
    12 / 994 (1.21%)
         occurrences causally related to treatment / all
    0 / 14
         deaths causally related to treatment / all
    0 / 0
    Aortic Valve Stenosis
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Arteriosclerosis Coronary Artery
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Atrial Fibrillation
         subjects affected / exposed
    5 / 994 (0.50%)
         occurrences causally related to treatment / all
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    Atrial Flutter
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Atrial Tachycardia
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Atrioventricular Block Second Degree
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cardiac Failure
         subjects affected / exposed
    3 / 994 (0.30%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Cardiac Failure Congestive
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Coronary Artery Disease
         subjects affected / exposed
    6 / 994 (0.60%)
         occurrences causally related to treatment / all
    0 / 6
         deaths causally related to treatment / all
    0 / 0
    Coronary Artery Stenosis
         subjects affected / exposed
    6 / 994 (0.60%)
         occurrences causally related to treatment / all
    0 / 7
         deaths causally related to treatment / all
    0 / 0
    Coronary Ostial Stenosis
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Mitral Valve Stenosis
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Myocardial Infarction
         subjects affected / exposed
    3 / 994 (0.30%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Myocardial Ischaemia
         subjects affected / exposed
    5 / 994 (0.50%)
         occurrences causally related to treatment / all
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    Subendocardial Ischaemia
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Ventricular Fibrillation
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Nervous system disorders
    Amnesia
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Ataxia
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Carotid Artery Stenosis
         subjects affected / exposed
    3 / 994 (0.30%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Carpal Tunnel Syndrome
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cerebrovascular Accident
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Facial Paralysis
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Headache
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Ischaemic Stroke
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Paraesthesia
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Seizure
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    Syncope
         subjects affected / exposed
    3 / 994 (0.30%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Transient Ischaemic Attack
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    2 / 994 (0.20%)
         occurrences causally related to treatment / all
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    Eye disorders
    Cataract
         subjects affected / exposed
    2 / 994 (0.20%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal disorders
    Colitis Ischaemic
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Diverticular Perforation
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Diverticulum Intestinal
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Dyspepsia
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrooesophageal Reflux Disease
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Haemorrhoidal Haemorrhage
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hypoaesthesia Oral
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Lower Gastrointestinal Haemorrhage
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Melaena
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Perianal Erythema
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Rectal Haemorrhage
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Umbilical Hernia
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hepatobiliary disorders
    Bile Duct Stone
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cholelithiasis
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Chronic Hepatitis
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Hepatocellular Injury
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Hypertransaminasaemia
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Skin and subcutaneous tissue disorders
    Actinic Keratosis
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Parapsoriasis
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Rash
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Renal and urinary disorders
    Bladder Trabeculation
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Nephrolithiasis
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Renal Impairment
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Musculoskeletal and connective tissue disorders
    Fibromyalgia
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Intervertebral Disc Protrusion
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Myopathy
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Osteoarthritis
         subjects affected / exposed
    3 / 994 (0.30%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Polymyalgia Rheumatica
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Spondylolisthesis
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Tendonitis
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Infections and infestations
    Bronchitis
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Campylobacter Colitis
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Diabetic Foot Infection
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Diverticulitis
         subjects affected / exposed
    3 / 994 (0.30%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Escherichia Sepsis
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastroenteritis Viral
         subjects affected / exposed
    2 / 994 (0.20%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Liver Abscess
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Pneumonia
         subjects affected / exposed
    3 / 994 (0.30%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Urinary Tract Infection
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Urosepsis
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Viral Infection
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Wound Infection
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Metabolism and nutrition disorders
    Dehydration
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Diabetes Mellitus
         subjects affected / exposed
    3 / 994 (0.30%)
         occurrences causally related to treatment / all
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    Diabetes Mellitus Inadequate Control
         subjects affected / exposed
    1 / 994 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Alirocumab
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    221 / 994 (22.23%)
    Nervous system disorders
    Headache
         subjects affected / exposed
    61 / 994 (6.14%)
         occurrences all number
    94
    Musculoskeletal and connective tissue disorders
    Myalgia
         subjects affected / exposed
    71 / 994 (7.14%)
         occurrences all number
    93
    Infections and infestations
    Influenza
         subjects affected / exposed
    53 / 994 (5.33%)
         occurrences all number
    61
    Nasopharyngitis
         subjects affected / exposed
    78 / 994 (7.85%)
         occurrences all number
    86

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    01 Mar 2016
    Following amendment were made: Reassessment of the number of subjects planned to be enrolled, based on update of the table of expected 95% confidence intervals for various adverse events rates. Streamline of the requirements for the end of study: only one final on-site visit called “End of Treatment/End of Study Visit” (EOT/EOS) was required. Modification in the list of the AE of special interest. Clarification regarding the LDL-C assessment: the Friedewald formula to assess LDL-C was planned to be used even in case TG was elevated (>400 mg/dL). Although there was no formal interim analysis, some statistical analyses might be performed before the end of the study in order to support a dossier of reimbursement if required by health authorities in some countries.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 02:28:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA